^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Cervical Cancer
    Drug:Mvasi (bevacizumab-awwb) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    01/15/2018
    Excerpt:
    Mvasi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.
    Secondary therapy:
    cisplatin + paclitaxel; paclitaxel + topotecan
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of…Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan
    Secondary therapy:
    cisplatin + paclitaxel; paclitaxel + topotecan